Regulations.gov document
MAPP 6025.6 Good Review Practice: Management of Breakthrough Therapy Designated Drugs and…
Supporting & Related Material · FDA-2022-N-2396 · posted Nov 1, 2022
Key facts
| Document ID | FDA-2022-N-2396-0002 |
|---|---|
| Title | MAPP 6025.6 Good Review Practice: Management of Breakthrough Therapy Designated Drugs and Biologics RE Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program; Program Announcement |
| Document type | Supporting & Related Material |
| Subtype | Background Material |
| Agency | FDA |
| Docket | FDA-2022-N-2396 |
| Posted | Nov 1, 2022 |
At a glance
- 1–9 Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: